Navellier & Associates Inc Amgen Inc Transaction History

Navellier & Associates Inc

$705 Million
Q3 2024

A detailed history of Navellier & Associates Inc transactions in Amgen Inc stock. As of the latest transaction made, Navellier & Associates Inc holds 14,817 shares of AMGN stock, worth $4.36 Million. This represents 0.68% of its overall portfolio holdings.

Number of Shares

14,817

Previous 15,498 4.39%

Holding current value

$4.36 Million

Previous $4.84 Million 1.4%

% of portfolio

0.68%

Previous 0.58%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$309.38 - $337.38 $210,687 - $229,755	-681 Reduced 4.39%	14,817 $4.77 Million
Q2 2024 Aug 08, 2024	SELL	$262.75 - $319.31 $60,695 - $73,760	-231 Reduced 1.47%	15,498 $4.84 Million
Q1 2024 May 13, 2024	SELL	$268.87 - $324.56 $1.39 Million - $1.68 Million	-5,186 Reduced 24.8%	15,729 $4.47 Million
Q4 2023 Feb 08, 2024	BUY	$255.7 - $288.46 $268,740 - $303,171	1,051 Added 5.29%	20,915 $6.02 Million
Q3 2023 Nov 09, 2023	SELL	$218.65 - $271.46 $128,784 - $159,889	-589 Reduced 2.88%	19,864 $5.34 Million
Q2 2023 Aug 07, 2023	BUY	$214.27 - $253.37 $5,142 - $6,080	24 Added 0.12%	20,453 $4.54 Million
Q1 2023 May 12, 2023	SELL	$225.79 - $275.2 $82,187 - $100,172	-364 Reduced 1.75%	20,429 $4.94 Million
Q4 2022 Feb 02, 2023	BUY	$229.03 - $291.01 $287,432 - $365,217	1,255 Added 6.42%	20,793 $5.46 Million
Q3 2022 Nov 09, 2022	SELL	$224.46 - $253.15 $23,119 - $26,074	-103 Reduced 0.52%	19,538 $4.4 Million
Q2 2022 Aug 12, 2022	BUY	$230.71 - $256.74 $131,504 - $146,341	570 Added 2.99%	19,641 $4.78 Million
Q1 2022 Apr 29, 2022	BUY	$219.27 - $242.57 $148,007 - $163,734	675 Added 3.67%	19,071 $4.61 Million
Q4 2021 Feb 14, 2022	SELL	$198.88 - $227.6 $153,734 - $175,934	-773 Reduced 4.03%	18,396 $4.14 Million
Q3 2021 Oct 28, 2021	SELL	$212.27 - $248.7 $59,860 - $70,133	-282 Reduced 1.45%	19,169 $4.08 Million
Q2 2021 Aug 09, 2021	BUY	$233.58 - $259.14 $209,521 - $232,448	897 Added 4.83%	19,451 $4.74 Million
Q1 2021 May 12, 2021	SELL	$221.91 - $258.6 $43,716 - $50,944	-197 Reduced 1.05%	18,554 $4.62 Million
Q4 2020 Feb 05, 2021	SELL	$216.38 - $257.67 $139,565 - $166,197	-645 Reduced 3.33%	18,751 $4.31 Million
Q3 2020 Nov 09, 2020	SELL	$234.65 - $260.95 $77,903 - $86,635	-332 Reduced 1.68%	19,396 $4.93 Million
Q2 2020 Aug 12, 2020	SELL	$197.81 - $242.74 $66,464 - $81,560	-336 Reduced 1.67%	19,728 $4.65 Million
Q1 2020 May 13, 2020	SELL	$182.24 - $241.7 $144,698 - $191,909	-794 Reduced 3.81%	20,064 $4.07 Million
Q4 2019 Feb 12, 2020	SELL	$189.21 - $243.2 $111,633 - $143,488	-590 Reduced 2.75%	20,858 $5.03 Million
Q3 2019 Oct 16, 2019	BUY	$174.11 - $208.62 $79,220 - $94,922	455 Added 2.17%	21,448 $4.15 Million
Q2 2019 Jul 17, 2019	SELL	$166.7 - $195.41 $18,670 - $21,885	-112 Reduced 0.53%	20,993 $3.87 Million
Q1 2019 May 15, 2019	SELL	$180.87 - $203.88 $122,087 - $137,619	-675 Reduced 3.1%	21,105 $4.01 Million
Q4 2018 Jan 15, 2019	SELL	$178.4 - $208.25 $120,598 - $140,777	-676 Reduced 3.01%	21,780 $4.24 Million
Q3 2018 Nov 14, 2018	SELL	$185.29 - $208.89 $133,408 - $150,400	-720 Reduced 3.11%	22,456 $4.66 Million
Q2 2018 Aug 06, 2018	BUY	$166.05 - $186.51 $58,615 - $65,838	353 Added 1.55%	23,176 $4.28 Million
Q1 2018 May 21, 2018	BUY	$169.43 - $198.0 $104,538 - $122,166	617 Added 2.78%	22,823 $3.89 Million
Q4 2017 Feb 12, 2018	SELL	$168.79 - $188.59 $640,389 - $715,510	-3,794 Reduced 14.59%	22,206 $3.86 Million
Q3 2017 Nov 14, 2017	SELL	$167.29 - $191.0 $2.09 Million - $2.39 Million	-12,500 Reduced 32.47%	26,000 $4.85 Million
Q2 2017 Aug 24, 2017	BUY	N/A	38,500	38,500 $6.63 Million

Others Institutions Holding AMGN

# of Institutions

3,122

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $157B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Navellier & Associates Inc with notifications on news.

Account

Navellier & Associates Inc Amgen Inc Transaction History